作者与单位 Authors & Affiliations
Shipra Gandhi1, Sayeeda Yasmeen2, Spencer Rosario2, Wiam Bshara2, Thaer Khoury2, Hans Minderman2, Orla Maguire2, Zhihong Gong2, Ayana T. Ruffin1, Megan Meek Wyatt1, Mahmoud Abdelbary1, Chrystal Mary Paulos1, Elizabeth Repasky2, Pawel Kalinski3, Christine Ambrosone2, Song Yao2, Chi-Chen Hong2
1Winship Cancer Institute of Emory University, Atlanta, GA,2Roswell Park Comphrehensive Cancer center, Buffalo, NY,3University of Pittsburgh, Pittsburgh, PA
摘要 Abstract
Background: Chronic psychosocial distress may accelerate breast cancer progression by altering immune, and inflammatory pathways, yet its genome-wide transcriptional effects in breast tumors remain unclear. This study uses RNA sequencing (RNA-seq) to characterize how distress influences transcriptional programs within the breast tumor microenvironment (TME).
Methods: Tumor samples from the Women's Health after Breast Cancer Study were analyzed for genome-wide transcriptional effects of distress. Participants completed the Perceived Stress Scale (PSS) and the Center for Epidemiologic Studies Depression Scale (CES-D) at diagnosis, including total scores and subscales (somatic symptoms, depressive affect, interpersonal problems, and positive affect). RNA-seq was performed on FFPE tumors from 195 women (152 ER+, 43 ER−). Principal component analysis (PCA) identified distress domains contributing to transcriptional variability. Participants were classified using PSS (>14 vs 0-14) and CES-D somatic symptoms (>3 vs ≤3). Differential gene-expression and gene-set enrichment analyses evaluated high-stress/low-somatic symptoms and low-stress/high-somatic symptoms groups vs a common low-stress/low-somatic symptoms reference, adjusting for age and education. Statistical significance was defined as FDR<0.05.
Results: PCA indicated subtype-specific distress signatures, with CES-D somatic symptoms explaining the most transcriptional variance in ER+ tumors and PSS explaining more variance in ER− tumors. In ER+ tumors, high stress with low somatic symptoms upregulated immune-activation pathways, including B-cell signaling, interferon responses, complement, and antigen presentation (top NES ~2.1-2.7, FDR<0.05). Key genes ( FLG, IGLV3-16, IGKV3D-15, RPS7P3 ) mapped to immune-activation and interferon pathways. In ER− tumors, high stress showed enrichment of PD-1 co-inhibition and MHC-I antigen-presentation (NES=2.36 and 2.15, respectively, FDR<0.03), with suppression of neuronal, metabolic, mitochondrial, and protein-synthesis signaling (NES −1.4 to −2.1, FDR<0.05). High somatic symptoms in ER+ tumors enriched translational and ribosomal pathways (NES=3.0, FDR<0.01). In ER− tumors, high somatic symptoms were associated with increased keratinization, leptin, WNT, and IGF signaling (NES~1.8-2.7, FDR<0.02), and reduced chromatin-regulation, DNA replication, RNA-processing, translation pathways, and MHC-I antigen presentation (NES ~1.8 to -1.9, FDR<0.006).
Conclusions: Psychological distress shapes breast-tumor transcriptional programs in a subtype-specific manner. Stress and depressive domains map to distinct immune, metabolic, and biosynthetic pathways in ER+ vs ER− disease, suggesting that different forms of distress engage different processes in the TME. This information could be leveraged to design new treatments for patients.
利益披露 Disclosure
S. Gandhi,
Hologic Other, consulting.
Astrazeneca Other, consulting.
Novartis Other, consulting.
MedPage Today Other, consulting.
Genentech Other, consulting.
Stemline Therapeutics Other, consulting.
MGH Life Sciences, Clinical Care Options, PeerView Other, Honoraria.
Roche Other, Speaker.
S. Yasmeen, None..
S. Rosario, None..
W. Bshara, None..
T. Khoury, None..
H. Minderman, None..
O. Maguire, None..
Z. Gong, None..
A. T. Ruffin, None..
M. M. Wyatt, None..
M. Abdelbary, None..
C. M. Paulos, None..
E. Repasky, None..
P. Kalinski, None..
C. Ambrosone, None..
S. Yao, None..
C. Hong, None.